Leucine Rich Repeat Containing Protein 32 (LRRC32) Antibody (FITC)
169€ (20 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Leucine Rich Repeat Containing Protein 32 (LRRC32) Antibody (FITC)
category
Primary Antibodies
provider
Abbexa
reference
abx306923
Description
LRRC32 Antibody (FITC) is a Rabbit Polyclonal against LRRC32 conjugated to FITC.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Leucine Rich Repeat Containing Protein 32 (LRRC32) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | FITC |
| Isotype | IgG |
| Purity | > 95% |
| Purification | Purified by Protein G. |
| Size 1 | 20 µg |
| Size 2 | 50 µg |
| Size 3 | 100 µg |
| Size 4 | 200 µg |
| Size 5 | 1 mg |
| Form | Liquid |
| Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q14392 |
| Gene ID | 2615 |
| OMIM | 137207 |
| Alias | Garpin,Transforming growth factor beta activator LRRC32,Glycoprotein A repetitions predominant,D11S833E |
| Background | Antibody anti-LRRC32 |
| Status | RUO |
Descripción
LRRC32, also known as glycoprotein A repetitions predominant (GARP), is a membrane protein highly expressed on regulatory T cells (Tregs) and platelets where it plays a critical role in regulating immune tolerance it acts as a receptor for latent TGF-β (transforming growth factor-beta) facilitating its activation and release on the cell surface LRRC32 is crucial for maintaining Treg function and suppressing excessive immune responses studies indicate its involvement in autoimmunity cancer and inflammation where dysregulation of LRRC32-mediated TGF-β signaling contributes to disease progression its role in tumor immunity is particularly notable as it enables tumors to evade immune surveillance by promoting an immunosuppressive microenvironment ongoing research is focused on targeting LRRC32 to modulate Treg activity in diseases such as cancer and autoimmune disorders making it a promising therapeutic candidate
Related Products
Recombinant Human LRRC32
Ver Producto
Mouse Leucine Rich Repeat Containing Protein 32 (LRRC32) Protein
Recombinant Leucine Rich Repeat Containing Protein 32 (LRRC32) is a recombinant Mouse protein produced in a Prokaryotic expression system (E. coli).
Ver Producto
Leucine Rich Repeat Containing Protein 32 (LRRC32) Antibody
Polyclonal Antibody to Leucine Rich Repeat Containing Protein 32 (LRRC32).
Ver Producto